Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page
- Check2 days agoChange DetectedThe related topics section now omits Lung cancer and MedlinePlus Genetics, reducing navigational context but not changing the study’s core details; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoChange DetectedResults data has been posted for the study (Results First Posted 2025-03-24). Enrollment and primary completion dates have been updated to reflect the latest status.SummaryDifference0.4%

- Check16 days agoChange DetectedLung cancer is added to related topics with a MedlinePlus Genetics link for educational resources.SummaryDifference0.2%

- Check38 days agoChange DetectedUpdated version to v3.2.0 and removed MedlinePlus Genetics topic: Lung cancer; added a government funding/operating status notice referencing NIH and OPM.SummaryDifference3%

- Check45 days agoChange DetectedCore content updated with a new MedlinePlus Genetics topic on Lung cancer and a version upgrade to v3.1.0; older revision reference v3.0.2 was removed.SummaryDifference0.2%

- Check52 days agoChange DetectedRemoved a MedlinePlus Genetics topic entry for Lung cancer from the page, reducing coverage of that topic without adding new content.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.